Soleno Therapeutics, Inc. (SLNO)
$53.01+0.00%Close
BUYBULL · day 11
Key stats
- Market cap
- $2.8B
- Beta
- -2.22
- P/E (TTM)
- 27.09
- 1W
- +0.13%
- 1M
- +0.44%
- vs SPY 1W
- -0.29%
- vs SPY 1M
- -1.62%
Industry peers
FMP comparable companies · ranked by market cap
- APGEBUYApogee Therapeutics, Inc.$8.4BBULLQ 60$135.07-0.01%
- PRAXSELLPraxis Precision Medicines, Inc.$7.8BCRISISQ 11$280.14-3.26%
- CNTACentessa Pharmaceuticals plc$6.3B$40.50
- MIRMSELLMirum Pharmaceuticals, Inc.$4.8BRECOVERYQ 37$79.25+0.06%
- XENESELLXenon Pharmaceuticals Inc.$3.5BCRISISQ 22$36.57-1.73%
- CELCSELLCelcuity Inc.$3.5BCRISISQ 26$71.25-3.08%
- VKTXSELLViking Therapeutics, Inc.$3.3BCRISISQ 22$28.38-0.60%
- DYNSELLDyne Therapeutics, Inc.$2.9BRECOVERYQ 3$15.40-4.09%
- AAPGSELLAscentage Pharma Group International$1.5BRECOVERYQ 5$16.09+3.80%
- RAREBUYUltragenyx Pharmaceutical Inc.$1.4BRECOVERYQ -6$14.46-1.16%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on SLNO?
- LOPJLB’s latest quantitative signal on Soleno Therapeutics, Inc. (SLNO) is BUY in a BULL regime. Signals are updated daily.
- What market regime is SLNO in?
- Soleno Therapeutics, Inc. (SLNO) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Soleno Therapeutics, Inc. (SLNO) do?
- Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III…